Cancer Research Cell Death Mechanisms and Cancer Therapy Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tamura, K.
Right arrow Articles by Lazo, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamura, K.
Right arrow Articles by Lazo, J. S.
[Cancer Research 60, 1317-1325, March 1, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Cdc25 Inhibition and Cell Cycle Arrest by a Synthetic Thioalkyl Vitamin K Analogue1

Kenji Tamura, Eileen C. Southwick, Jeffrey Kerns, Katherine Rosi, Brian I. Carr, Craig Wilcox and John S. Lazo2

Departments of Pharmacology [K. T., E. C. S., J. S. L.], Chemistry [J. K., K. R., C. W.], and Surgery [B. C.], University of Pittsburgh, Pittsburgh, Pennsylvania 15261, and Second Department of Internal Medicine [K. T.], Hiroshima University School of Medicine, Hiroshima 734, Japan

A synthetic vitamin K analogue, 2-(2-mercaptoethanol)-3-methyl-1,4-naphthoquinone or compound 5 (Cpd 5), was found previously to be a potent inhibitor of tumor cell growth. We now demonstrate that Cpd 5 arrested cell cycle progression at both G1 and G2-M. Because of the potential arylating activity of Cpd 5, it might inhibit Cdc25 phosphatases, which contain a cysteine in the catalytic site. To test this hypothesis, we examined the inhibitory activity of Cpd 5 against several cell cycle-relevant protein tyrosine phosphatases and found that Cpd 5 was a potent, selective, and partially competitive inhibitor of Cdc25 phosphatases. Furthermore, Cpd 5 caused time-dependent, irreversible enzyme inhibition, consistent with arylation of the catalytic cysteine in Cdc25. Treatment of cells with Cpd 5 blocked dephosphorylation of the Cdc25C substrate, Cdc2, and its kinase activity. Cpd 5 enhanced tyrosine phosphorylation of both potent regulators of G1 transition, i.e., Cdk2 and Cdk4, and decreased the phosphorylation of Rb, an endogenous substrate for Cdk4 kinase. Furthermore, close chemical analogues that lacked in vitro Cdc25 inhibitory activity failed to block cell cycle progression and Cdc2 kinase activity. Cpd 5 did not alter the levels of p53 or the endogenous cyclin-dependent kinase inhibitors, p21 and p16. Our results support the hypothesis that the disruption in cell cycle transition caused by Cpd 5 was attributable to intracellular Cdc25 inhibition. This novel thioalkyl K vitamin analogue could be useful for cell cycle control studies and may provide a valuable pharmacophore for the design of future therapeutics.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
A. Vogt, P. R. McDonald, A. Tamewitz, R. P. Sikorski, P. Wipf, J. J. Skoko III, and J. S. Lazo
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells
Mol. Cancer Ther., February 1, 2008; 7(2): 330 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J.-I Chao, W.-C. Su, and H.-F. Liu
Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT
Mol. Cancer Ther., November 1, 2007; 6(11): 3039 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Cazales, R. Boutros, M.-C. Brezak, S. Chaumeron, G. Prevost, and B. Ducommun
Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly
Mol. Cancer Ther., January 1, 2007; 6(1): 318 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Kar, M. Wang, W. Yao, C. J. Michejda, and B. I. Carr
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
Mol. Cancer Ther., June 1, 2006; 5(6): 1511 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Kar, M. Wang, K. S. Rosi, C. S. Wilcox, and B. I. Carr
Inhibition of rat liver regeneration after partial hepatectomy and induction of ERK phosphorylation by Cpd 5, a K vitamin-based anticancer compound
Carcinogenesis, December 1, 2004; 25(12): 2345 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Rudolph
Targeting the Neighbor's Pool
Mol. Pharmacol., October 1, 2004; 66(4): 780 - 782.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-I Chao, P.-C. Kuo, and T.-S. Hsu
Down-regulation of Survivin in Nitric Oxide-induced Cell Growth Inhibition and Apoptosis of the Human Lung Carcinoma Cells
J. Biol. Chem., May 7, 2004; 279(19): 20267 - 20276.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Han, H. Shen, B. I. Carr, P. Wipf, J. S. Lazo, and S.-s. Pan
NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 64 - 70.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
A. Harding, N. Giles, A. Burgess, J. F. Hancock, and B. G. Gabrielli
Mechanism of Mitosis-specific Activation of MEK1
J. Biol. Chem., May 2, 2003; 278(19): 16747 - 16754.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Pu, A. A. Amoscato, M. E. Bier, and J. S. Lazo
Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione
J. Biol. Chem., November 27, 2002; 277(49): 46877 - 46885.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Wang, M. Wang, J. S. Lazo, and B. I. Carr
Identification of Epidermal Growth Factor Receptor as a Target of Cdc25A Protein Phosphatase
J. Biol. Chem., May 24, 2002; 277(22): 19470 - 19475.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. S. Lazo, K. Nemoto, K. E. Pestell, K. Cooley, E. C. Southwick, D. A. Mitchell, W. Furey, R. Gussio, D. W. Zaharevitz, B. Joo, et al.
Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors.
Mol. Pharmacol., April 1, 2002; 61(4): 720 - 728.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Wang, E. C. Southwick, M. Wang, S. Kar, K. S. Rosi, C. S. Wilcox, J. S. Lazo, and B. I. Carr
Involvement of Cdc25A Phosphatase in Hep3B Hepatoma Cell Growth Inhibition Induced by Novel K Vitamin Analogs
Cancer Res., October 1, 2001; 61(19): 7211 - 7216.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. S. Lazo, K. Tamura, A. Vogt, J.-K. Jung, S. Rodriguez, R. Balachandran, B. W. Day, and P. Wipf
Antimitotic Actions of a Novel Analog of the Fungal Metabolite Palmarumycin CP1
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 364 - 371.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Vogt, K. Tamura, S. Watson, and J. S. Lazo
Antitumor Imidazolyl Disulfide IV-2 Causes Irreversible G2/M Cell Cycle Arrest without Hyperphosphorylation of Cyclin-Dependent Kinase Cdk1
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1070 - 1075.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
A. Vogt, T. Adachi, A. P. Ducruet, J. Chesebrough, K. Nemoto, B. I. Carr, and J. S. Lazo
Spatial Analysis of Key Signaling Proteins by High-content Solid-phase Cytometry in Hep3B Cells Treated with an Inhibitor of Cdc25 Dual-specificity Phosphatases
J. Biol. Chem., June 1, 2001; 276(23): 20544 - 20550.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.